ZA96431B - Use of l-carnitine and its alkanoyl derivatives for reducing the toxic effects of cylcosporin-a and other immuno-suppressant drugs - Google Patents
Use of l-carnitine and its alkanoyl derivatives for reducing the toxic effects of cylcosporin-a and other immuno-suppressant drugsInfo
- Publication number
- ZA96431B ZA96431B ZA96431A ZA96431A ZA96431B ZA 96431 B ZA96431 B ZA 96431B ZA 96431 A ZA96431 A ZA 96431A ZA 96431 A ZA96431 A ZA 96431A ZA 96431 B ZA96431 B ZA 96431B
- Authority
- ZA
- South Africa
- Prior art keywords
- carnitine
- cylcosporin
- immuno
- reducing
- toxic effects
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/30—Preparation of optical isomers
- C07C227/34—Preparation of optical isomers by separation of optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT95RM000037A IT1277147B1 (it) | 1995-01-20 | 1995-01-20 | Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi. |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA96431B true ZA96431B (en) | 1996-08-08 |
Family
ID=11402949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA96431A ZA96431B (en) | 1995-01-20 | 1996-01-19 | Use of l-carnitine and its alkanoyl derivatives for reducing the toxic effects of cylcosporin-a and other immuno-suppressant drugs |
Country Status (13)
Country | Link |
---|---|
US (2) | US5955424A (es) |
EP (1) | EP0722724B1 (es) |
JP (1) | JPH08231390A (es) |
KR (1) | KR100443730B1 (es) |
AT (1) | ATE177946T1 (es) |
CA (1) | CA2167456A1 (es) |
DE (1) | DE69508551T2 (es) |
DK (1) | DK0722724T3 (es) |
ES (1) | ES2130509T3 (es) |
GR (1) | GR3030545T3 (es) |
IT (1) | IT1277147B1 (es) |
TW (1) | TW445145B (es) |
ZA (1) | ZA96431B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA65587C2 (en) * | 1997-10-09 | 2004-04-15 | Baker Norton Pharma | Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus |
IT1306179B1 (it) * | 1999-07-28 | 2001-05-30 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e cura delle disfunzioni e patologierenali di tipo tossico e funzionale. |
IT1316998B1 (it) * | 2000-03-02 | 2003-05-26 | Sigma Tau Healthscience Spa | Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori. |
EP1330254B1 (en) * | 2000-10-12 | 2005-07-06 | Pharma Mar, S.A. | Treatment of cancers by aplidine in conjunction with carnitine or acetylcarnitine |
ITRM20010293A1 (it) * | 2001-05-29 | 2002-11-29 | Sigma Tau Ind Farmaceuti | Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore. |
US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
US20070087975A1 (en) * | 2005-10-17 | 2007-04-19 | Sigma-Tau Industrie Farmaceutiche Riunite Spa | Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients |
CN102038671B (zh) * | 2010-06-29 | 2012-07-04 | 辽宁思百得医药科技有限公司 | 包含左卡尼汀和羟苯磺酸盐的药物组合物 |
KR101760510B1 (ko) | 2014-12-18 | 2017-07-21 | 가톨릭대학교 산학협력단 | 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물 |
WO2016099214A1 (ko) * | 2014-12-18 | 2016-06-23 | 가톨릭대학교 산학협력단 | 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물 |
IT201900007446A1 (it) * | 2019-05-29 | 2020-11-29 | Giuseppe Castellano | Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho |
CN115469026B (zh) * | 2022-07-14 | 2023-10-20 | 中日友好医院(中日友好临床医学研究所) | 用于检测环孢素a肾毒性相关标志物的检测试剂、试剂盒及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1195852B (it) * | 1986-07-04 | 1988-10-27 | Sigma Tau Ind Farmaceuti | Impiego di l-carnitina nel trattamento degli effetti tossici indotti dall'inalazione di alotano e di altri anestitici generali alogenati |
JPH01213258A (ja) * | 1988-02-23 | 1989-08-28 | Kyowa Hakko Kogyo Co Ltd | カルニチンおよびカルニチンアミドの精製法 |
-
1995
- 1995-01-20 IT IT95RM000037A patent/IT1277147B1/it active IP Right Grant
- 1995-12-22 EP EP95120394A patent/EP0722724B1/en not_active Expired - Lifetime
- 1995-12-22 ES ES95120394T patent/ES2130509T3/es not_active Expired - Lifetime
- 1995-12-22 DK DK95120394T patent/DK0722724T3/da active
- 1995-12-22 AT AT95120394T patent/ATE177946T1/de not_active IP Right Cessation
- 1995-12-22 DE DE69508551T patent/DE69508551T2/de not_active Expired - Fee Related
- 1995-12-26 TW TW084113879A patent/TW445145B/zh not_active IP Right Cessation
-
1996
- 1996-01-03 US US08/580,993 patent/US5955424A/en not_active Expired - Fee Related
- 1996-01-17 CA CA002167456A patent/CA2167456A1/en not_active Abandoned
- 1996-01-19 ZA ZA96431A patent/ZA96431B/xx unknown
- 1996-01-19 KR KR1019960001086A patent/KR100443730B1/ko not_active IP Right Cessation
- 1996-01-22 JP JP8008347A patent/JPH08231390A/ja active Pending
-
1997
- 1997-09-08 US US08/925,485 patent/US5958941A/en not_active Expired - Fee Related
-
1999
- 1999-06-16 GR GR990401622T patent/GR3030545T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2167456A1 (en) | 1996-07-21 |
DK0722724T3 (da) | 1999-10-11 |
ATE177946T1 (de) | 1999-04-15 |
JPH08231390A (ja) | 1996-09-10 |
TW445145B (en) | 2001-07-11 |
ITRM950037A1 (it) | 1996-07-20 |
DE69508551T2 (de) | 1999-09-02 |
ES2130509T3 (es) | 1999-07-01 |
KR960029314A (ko) | 1996-08-17 |
EP0722724B1 (en) | 1999-03-24 |
GR3030545T3 (en) | 1999-10-29 |
DE69508551D1 (de) | 1999-04-29 |
KR100443730B1 (ko) | 2004-10-14 |
ITRM950037A0 (it) | 1995-01-20 |
US5958941A (en) | 1999-09-28 |
EP0722724A1 (en) | 1996-07-24 |
US5955424A (en) | 1999-09-21 |
IT1277147B1 (it) | 1997-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA96431B (en) | Use of l-carnitine and its alkanoyl derivatives for reducing the toxic effects of cylcosporin-a and other immuno-suppressant drugs | |
HK1040631A1 (en) | Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues. | |
CA2279522A1 (en) | Biocompatible compounds for pharmaceutical drug delivery systems | |
MY125662A (en) | Pharmaceutical formulations containing darifenacin | |
EP1466606A3 (en) | Use of inosine for the manufacture of a medicament for stimulating axonal outgrowth of central nervous system neurons | |
CA2209001A1 (en) | Hydrophobic taxane derivatives | |
CA2275889A1 (en) | Formulation and method for treating neoplasms by inhalation | |
CA2304704A1 (en) | Formulations and methods for reducing toxicity of antineoplastic agents | |
HU9302675D0 (en) | Process for producing pharmaceutical compositions containing 21-norrapamycin as active agent | |
CA2053826A1 (en) | Pharmaceutical compositions active in the therapy of neurological affections in aids patients | |
IL123551A0 (en) | Tricyclic erythromycin derivatives | |
EP0620004A4 (en) | MEDICAL COMPOSITION. | |
TW221441B (es) | ||
UA29435C2 (uk) | Похідні 3бета-алкенілпенаму та їх фармацевтично прийнятні солі | |
ZA892188B (en) | Peptide derivatives | |
CA2190837A1 (en) | Transdermal delivery of anti-epileptic drugs | |
AU6970394A (en) | Desoxyazaphospholipid derivatives having inhibiting activity on phospholipase a2 | |
GB9420748D0 (en) | 1,5 benzodiazepine derivatives | |
IT1271354B (it) | Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo contenente n-acetil cisteine e loro analoghi | |
CA2154485A1 (en) | Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders | |
CA2184395A1 (en) | Effective dosage form for antiepileptic drugs | |
AU3080692A (en) | Slow-release medicament containing a dihydropyridine derivate as a nanosol and its preparation | |
CA2235942A1 (en) | Tricyclic erythromycin derivatives |